Regulus Appoints VP, Investor Relations And Corporate Communications
Regulus Therapeutics Inc. has appointed Allison Wey vice president, investor relations and corporate communications. Wey brings over 25 years of experience in investor and media relations to the biopharma company, which specialises in medicines targeting microRNAs. She was previously vice president, investor relations at Durata Therapeutics, before which she held senior roles at Par Pharmaceuticals, Boron LePore and Associates and Edelman Financial Worldwide.
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
Diffusion Pharmaceuticals and WPD Pharmaceuticals get new chief medical officers.
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.